Pipeline
As of April 25, 2022
State of New Product Development[PDF: 205.0 KB]
Disease Area:
- * Asia:excluding Japan and China
Disease Area | Development code | Indications |
Stage
123Filed
|
Region |
Central nervous system
MP-214
Bipolar disorder
Asia
- Generic name
- Cariprazine
- Category(Indications)
- Dopamine D3/D2 receptor partial agonist(Bipolar disorder)
- Origin/licensee
- Licensed from Gedeon Richter (Hungary)
Central nervous system
MT-0551
Neuromyelitis optica spectrum disorder:NMOSD
Asia
- Product name
- Uplizna
- Generic name
- Inebilizumab
- Category(Indications)
- Humanized anti-CD19 monoclonal antibody(Neuromyelitis optica spectrum disorder:NMOSD)
- Origin/licensee
- Licensed from Horizon Therapeutics (Ireland)
Central nervous system
MT-0551
Myasthenia gravis
Japan
- Product name
- Uplizna
- Generic name
- Inebilizumab
- Category(Indications)
- Humanized anti-CD19 monoclonal antibody(Myasthenia gravis)
- Origin/licensee
- Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
Central nervous system
MT-5199
Tardive dyskinesia
Asia
- Product name
- Dysval
- Generic name
- Valbenazine
- Category(Indications)
- Vesicular monoamine transporter type 2 inhibitor(Tardive dyskinesia)
- Origin/licensee
- Licensed from Neurocrine Biosciences (US)
Central nervous system
MT-1186
Amyotrophic lateral sclerosis: ALS / Oral suspension
US, Japan *
- Generic name
- Edaravone
- Category(Indications)
- Free radical scavenger(Amyotrophic lateral sclerosis: ALS / Oral suspension)
- Origin/licensee
- In-house * NDA submission has been completed in the US, Japan, etc. and development stages for other countries are Phase 3.
Central nervous system
MT-210
Schizophrenia
US,Europe
- Generic name
- Roluperidone
- Category(Indications)
- 5-HT2A/Sigma 2 receptor antagonist(Schizophrenia)
- Origin/licensee
- Licensed to Minerva Neurosciences (US)
Central nervous system
ND0612
Parkinson's disease
Global
- Generic name
- Levodopa/Carbidopa
- Category(Indications)
- Continuous SC pump(Parkinson's disease)
- Origin/licensee
- In-house
Central nervous system
MT-8554
Peripheral neuropathic pain
Japan
- Generic name
- Elismetrep
- Category(Indications)
- TRPM8 antagonist(Peripheral neuropathic pain)
- Origin/licensee
- In-house
Central nervous system
MT-8554
Vasomotor symptoms associated with menopause
Global
- Generic name
- Elismetrep
- Category(Indications)
- TRPM8 antagonist(Vasomotor symptoms associated with menopause)
- Origin/licensee
- In-house
Central nervous system
MT-3921
Spinal cord injury
Global
- Generic name
- Unasnemab
- Category(Indications)
- Anti-RGMa antibody(Spinal cord injury)
- Origin/licensee
- Co-developed with Osaka University (Japan)
Immuno-inflammation
MT-5547
Osteoarthritis
Japan
- Generic name
- Fasinumab
- Category(Indications)
- Fully human anti-NGF monoclonal antibody(Osteoarthritis)
- Origin/licensee
- Licensed from Regeneron(US)
Immuno-inflammation
MT-7117
Erythropoietic protoporphyria, X-Linked protoporphyria
Global
- Generic name
- Dersimelagon
- Category(Indications)
- Selective melanocortin 1 receptor agonist(Erythropoietic protoporphyria, X-Linked protoporphyria)
- Origin/licensee
- In-house
Immuno-inflammation
MT-7117
Systemic sclerosis
Global
- Generic name
- Dersimelagon
- Category(Indications)
- Selective melanocortin 1 receptor agonist(Systemic sclerosis)
- Origin/licensee
- In-house
Immuno-inflammation
MT-0551
IgG4-related disease
Japan
- Product name
- Uplizna
- Generic name
- Inebilizumab
- Category(Indications)
- Humanized anti-CD19 monoclonal antibody(IgG4-related disease)
- Origin/licensee
- Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
Immuno-inflammation
MT-2990
Endometriosis
Global
- Category(Indications)
- Fully human anti-interleukin-33 (IL-33) monoclonal antibody(Endometriosis)
- Origin/licensee
- In-house
Vaccines
MT-2355
Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants
Japan
- Category(Indications)
- Combined vaccine(Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)
- Origin/licensee
- Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
Vaccines
MT-2766
Prophylaxis of COVID-19
Global *
- Product name
- Covifenz
- Category(Indications)
- Plant-derived VLP vaccine(Prophylaxis of COVID-19)
- Origin/licensee
- Medicago product (Canada) * Regulatory approval has been obtained in Canada, and development stages for other countries are Phase 3.
Vaccines
MT-8972
Prophylaxis of H5N1 influenza
Canada
- Category(Indications)
- Plant-derived VLP vaccine(Prophylaxis of H5N1 influenza)
- Origin/licensee
- Medicago product (Canada)
Vaccines
MT-7529
Prophylaxis of H7N9 influenza
- Category(Indications)
- Plant-derived VLP vaccine(Prophylaxis of H7N9 influenza)
- Origin/licensee
- Medicago product (Canada)
Vaccines
MT-5625
Prophylaxis of rotavirus gastroenteritis
- Category(Indications)
- Plant-derived VLP vaccine(Prophylaxis of rotavirus gastroenteritis)
- Origin/licensee
- Medicago product (Canada)
Vaccines
MT-2654
Prophylaxis of seasonal influenza/elderly
- Category(Indications)
- Adjuvanted plant-derived VLP vaccine(Prophylaxis of seasonal influenza/elderly)
- Origin/licensee
- Medicago product (Canada)
Others
MP-513
Type 2 diabetes mellitus
Asia
- Product name
- Tenelia
- Generic name
- Teneligliptin
- Category(Indications)
- DPP-4 inhibitor(Type 2 diabetes mellitus)
- Origin/licensee
- In-house
Others
TA-7284
Chronic kidney disease with type 2 diabetes mellitus
Japan
- Product name
- Canaglu/INVOKANA
- Generic name
- Canagliflozin
- Category(Indications)
- SGLT2 inhibitor(Chronic kidney disease with type 2 diabetes mellitus)
- Origin/licensee
- In-house
Others
MT-6548
Renal anemia
Asia
- Product name
- Vafseo
- Generic name
- Vadadustat
- Category(Indications)
- Hypoxia-inducible factor prolyl hydroxylase inhibitor(Renal anemia)
- Origin/licensee
- Licensed from Akebia (US)
Others
MT-4580
Secondary Hyperparathyroidism
China,Asia
- Product name
- Orkedia
- Generic name
- Evocalcet
- Category(Indications)
- Ca sensing receptor agonist(Secondary Hyperparathyroidism)
- Origin/licensee
- Licensed to Kyowa Kirin (Japan)
Others
MT-2765
Hypertension
China
- Category(Indications)
- Renin inhibitor(Hypertension)
- Origin/licensee
- Licensed to Shanghai Pharmaceuticals (China)
Others
MT-8633/ TR1801-ADC
Solid tumor
- Category(Indications)
- Anti-c-Met antibody drug conjugate(Solid tumor)
- Origin/licensee
- In-house / Collaborate with Open Innovation Partners (Japan)
There is no development status of the applicable area.
Please select one or more disease areas.
- * Asia:excluding Japan and China
Development code | Indications | Previous Announcement | As of Apr. 25, 2022 | ||
Stage
123FiledApproved
|
Region |
Stage
123FiledApproved
|
Region |
MP-214
Bipolar disorder
Asia
Thailand
- Generic name
- Cariprazine
- Category(Indications)
- Dopamine D3/D2 receptor partial agonist(Bipolar disorder)
- Origin/licensee
- Licensed from Gedeon Richter (Hungary)
MT-5199
Tardive dyskinesia
Japan
Japan
- Product name
- Dysval
- Generic name
- Valbenazine
- Category(Indications)
- Vesicular monoamine transporter type 2 inhibitor(Tardive dyskinesia)
- Origin/licensee
- Licensed from Neurocrine Biosciences (US)
MT-2766
Prophylaxis of COVID-19
Canada
Canada *
- Product name
- Covifenz
- Category(Indications)
- Plant-derived VLP vaccine(Prophylaxis of COVID-19)
- Origin/licensee
- Medicago product (Canada) * Regulatory approval has been obtained in Canada, and development stages for other countries are Phase 3.
MT-1186
Amyotrophic lateral sclerosis: ALS / Oral suspension
US
US, Japan **
- Generic name
- Edaravone
- Category(Indications)
- Free radical scavenger(Amyotrophic lateral sclerosis: ALS / Oral suspension)
- Origin/licensee
- In-house ** NDA submission has been completed in the US, Japan, etc. and development stages for other countries are Phase 3.
MT-2355
Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants
Japan
Japan
- Category(Indications)
- Combined vaccine(Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)
- Origin/licensee
- Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)